Hematology Laboratory, APHP Pitié-Salpêtrière Hospital and Sorbonne Université, Paris, France.
Department of Neurology, APHP Pitié-Salpêtrière, Hospital and Sorbonne Université, Paris, France.
Am J Hematol. 2019 Oct;94(10):1123-1131. doi: 10.1002/ajh.25578. Epub 2019 Aug 13.
Diagnosis of lymphoma leptomeningeal dissemination is challenging and relies on a wide array of methods. So far, no consensus biological guidelines are available. This increases the chance of intra- and interpractice variations, despite the shared concern to perform the minimum amount of tests while preserving clinically relevant results.We evaluated a training cohort of 371 cerebrospinal fluid (CSF) samples from patients with putative lymphomatous central nervous system (CNS) localization using conventional cytology (CC), flow cytometry (FCM), molecular clonality assesment by PCR and cytokine quantification (CQ). This led us to propose a biological algorithm, which was then verified on a validation cohort of 197 samples. The samples were classified according to the clinical context and the results of each technique were compared. Using all four techniques was not useful for exclusion diagnosis of CNS lymphoma (CNSL), but they proved complementary for cases with suspected CNSL. This was particularly true for CQ in primary CNSL. Overall, diagnosis can be obtained with a two-step approach. The first step comprises CC and FCM, as results are available quickly and FCM is a sensitive method. Both PCR and CQ can be postponed and performed in a second step, depending on the results from the first step and the clinical context.The proposed algorithm missed none of the CNSL samples of the validation cohort. Moreover, applying this algorithm would have spared 30% of PCR tests and 20% of CQ over a one-year period, without compromising clinical management.
淋巴瘤脑膜播散的诊断具有挑战性,依赖于广泛的方法。到目前为止,还没有共识的生物学指南。这增加了内部和实践之间差异的机会,尽管人们共同关注的是在保留临床相关结果的同时,尽量减少测试数量。
我们使用常规细胞学(CC)、流式细胞术(FCM)、PCR 分子克隆评估和细胞因子定量(CQ)评估了 371 例疑似淋巴瘤中枢神经系统(CNS)定位的患者的脑脊液(CSF)样本的训练队列。这使我们提出了一种生物学算法,然后在 197 个样本的验证队列中进行了验证。根据临床背景对样本进行分类,并比较了每种技术的结果。使用所有四种技术对于排除 CNS 淋巴瘤(CNSL)的诊断并没有用,但对于疑似 CNSL 的病例证明是互补的。CQ 在原发性 CNSL 中尤其如此。
总的来说,可以采用两步法进行诊断。第一步包括 CC 和 FCM,因为结果很快就能得到,而 FCM 是一种敏感的方法。PCR 和 CQ 都可以推迟,并根据第一步的结果和临床情况在第二步进行。
所提出的算法没有遗漏验证队列中的任何 CNSL 样本。此外,在不影响临床管理的情况下,在一年内,该算法可以避免 30%的 PCR 测试和 20%的 CQ。